Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity
2008 (English)In: Cancer Research, ISSN 0008-5472, Vol. 68, no 12, 4683-4692 p.Article in journal (Refereed) Published
Vascular endothelial growth factor (VEGF)-A165b is a COOH-terminal splice variant of VEGF-A that has been implicated in negative regulation of angiogenesis. We compared the properties of VEGF-A165b with those of VEGF-A121, VEGF-A145, and VEGF-A165. Induction of tyrosine phosphorylation sites in VEGFR-2 differed between the VEGF ligands as determined by tryptic phosphopeptide mapping and by use of phosphosite-specific antibodies. VEGF-A165b was considerably poorer in inducing phosphorylation of the positive regulatory site Y1052 in VEGFR-2. Whereas this did not affect activation of VEGFR-2 in vitro, we show that VEGF-A165b failed to induce vasculogenesis and sprouting angiogenesis in differentiating embryonic stem cells and vascularization of s.c. Matrigel plugs. In addition, the ability of the different VEGF ligands to induce angiogenesis correlated with their abilities to bind the VEGF coreceptor neuropilin 1 (NRP1). Our data indicate that loss of VEGFR-2/NRP1 complex formation and Y1052 phosphorylation contribute to the lack of angingenic properties of VEGF-A165b.
Place, publisher, year, edition, pages
2008. Vol. 68, no 12, 4683-4692 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-17664DOI: 10.1158/0008-5472.CAN-07-6577ISI: 000256855700026PubMedID: 18559514OAI: oai:DiVA.org:uu-17664DiVA: diva2:45435